CHIRON'S PRESIDENT RESIGNSChiron Corp. announced Monday that Hollings Renton hasresigned as president and chief operating officer, effective July1, 1993, for personal reasons.

Renton will continue his association with Chiron after July 1 ona half-time basis as executive consultant and managing directorof the company's Betaseron alliance with Schering AG and itssubsidiary, Berlex Laboratories, Chiron said.

Renton has been in his current position since 1991, and prior toits merger with Chiron, was president and chief operatingofficer of Cetus Corp. He joined Cetus in 1981 as controller andtreasurer, became vice president of finance in 1983, chiefoperating officer in 1987 and president in 1990.

Edward Penhoet, vice chairman and chief executive officer ofChiron (NASDAQ:CHIR) of Emeryville, Calif., will assumeRenton's responsibilities for managing Chiron's Cetus Oncologyand EuroCetus business units and human resources.

James M. Wilson, chief of molecular medicine and genetics atthe University of Michigan Medical Center, was appointeddirector of the newly established Institute for Human GeneTherapy at the University of Pennsylvania Medical Center inPhiladelphia. Wilson heads the research team whose genetherapy protocol for treating cystic fibrosis was approved bythe NIH's Recombinant DNA Advisory Committee (RAC) lastweek. Wilson also received approval recently from the FDA totreat patients with familial hypercholesterolemia via genetherapy.

Zynaxis Inc. of Malvern, Pa., named James Lyons senior vicepresident, chief financial officer and treasurer. He was vicepresident of finance for Boots Pharmaceutical Inc.

Repligen Corp. of Cambridge, Mass., named Allan P. Jarvis Jr.vice president of business planning, Mark F. Boshar chiefpatent counsel/director of intellectual property, and Don C.Stark director of marketing. Jarvis was director of businessdevelopment for Abbott Laboratories' biotechnologysubsidiary. Boshar was at the Boston law firm of Hale and Dorr,and Stark was director of marketing at Immunex Corp.

David G. Shand was named executive vice president of researchand development and chief scientific officer of The LiposomeCompany Inc. of Princeton, N.J. Shand is resigning as vicepresident of the Janssen Research Foundation, a Johnson andJohnson Company.

Idec Pharmaceuticals Corp. of Mountain View, Calif., namedConnie Matsui senior director, planning and resourcedevelopment.

Hem Pharmaceuticals Corp. of Philadelphia named J. AllisonDeFoor II general counsel and vice president of businessdevelopment. DeFoor was senior vice president and chiefexecutive officer of Wackenhut Monitoring Systems Inc.

Richard H. Woodrich was named vice president and chieffinancial officer of Oculon Corp. of Cambridge, Mass. He wasvice president and chief financial officer at T Cell Diagnostics.

Yariagadda S. Babu was promoted to vice president,crystallography at BioCryst Pharmaceuticals Inc. ofBirmingham, Ala. He was executive director, crystallography.

Synergen Inc. of Boulder, Colo., named Mary E. Bareillesdirector of corporate clinical research and vice president ofclinical research for the company's new Japanese operations.She was director, clinical development and medical affairs atUpjohn Pharmaceuticals Ltd. in Japan.

The La Jolla Institute for Allergy and Immunology of La Jolla,Calif., named Charles A. Carpowich Jr. vice president and chieffinancial officer.

Shaman Pharmaceuticals Inc. of San Carlos, Calif., namedRichard F. Hector director of biological sciences and ThomasCarlson director of ethnobiomedical field research. Hector wassenior staff scientist with the Cutter Biological Division of MilesPharmaceuticals.

(c) 1997 American Health Consultants. All rights reserved.

No Comments